Evidence map›Paper›PMID 21709297›Full record

Trial reportDiabetes care2011

Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1.

Jaime Uribarri, Weijing Cai, Maya Ramdas, Susan Goodman, Renata Pyzik, Xue Chen, Li Zhu, Gary E Striker, Helen Vlassara

3 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 142 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 6 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00579774 nacompletednot on this map

Effects of Glycoxidative Stress on Human Aging

TypeinterventionalSponsorIcahn School of Medicine at Mount SinaiRan2007 to 2011Enrolled438ConditionsAgingArmsLow AGE Diet, Regular Diet
NCT01363141 nacompletednot on this map

Effects of Glycooxidative Stress on Human Aging- Study #3

TypeinterventionalSponsorIcahn School of Medicine at Mount SinaiRan2010 to 2014Enrolled383ConditionsMetabolic SyndromeArmsRegular AGE Diet, Low AGE Diet
NCT02739971 nacompletednot on this mapstarted 2016, after this paper: background citation

Dietary Reduction of Advanced Glycation End Products to Prevent Cognitive Decline in Elderly Diabetics - a Randomized Pilot Trial

TypeinterventionalSponsorSheba Medical CenterRan2016 to 2020Enrolled75ConditionsCognitive Decline, Aging, Type 2 DiabetesArmsLow AGEs diet, Standard of care dietary guidance for Type 2 diabetes
3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 6 syntheses or guidelines pooled it, 318 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jaime UribarriDepartment of Medicine, The Mount Sinai School of Medicine, New York, New York, USA.
Weijing Cai
Maya Ramdas
Susan Goodman
Renata Pyzik
Xue Chen
Li Zhu
Gary E Striker
Helen Vlassara
Icahn School of Medicine at Mount Sinai · US

Funding

ZIPRASIDONE (GEODON) AUGMENTATION IN SEROTONIN REUPTAKE INHIBITOR-RESISTANT OBM01RR000071 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI NEWCORN, JEFFREY H · 1985 to 2009
$41.5M
Effects of Glycoxidative Stress on Human AgingR01DK091231 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HE, JOHN CIJIANG · 2010 to 2014
$3.1M
AGING &VASCULAR DISEASE ROLE OF GLYCATIONR01AG009453 · NIA · PICOWER INSTITUTE FOR MEDICAL RESEARCH · PI VLASSARA, HELEN · 1991 to 2007
$2.6M
Effects of Glycoxidative Stress on Human AgingR37AG023188 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI VLASSARA, HELEN · 2004 to 2010
$1.8M
NCRR NIH HHS M01 RR000071NCRR NIH HHS M01-RR-00071NIA NIH HHS R01 AG009453NIA NIH HHS R37 AG023188NIDDK NIH HHS R01 DK091231
6 · The paper itself

Abstract

objectiveIncreased oxidative stress (OS) and impaired anti-OS defenses are important in the development and persistence of insulin resistance (IR). Several anti-inflammatory and cell-protective mechanisms, including advanced glycation end product (AGE) receptor-1 (AGER1) and sirtuin (silent mating-type information regulation 2 homolog) 1 (SIRT1) are suppressed in diabetes. Because basal OS in type 2 diabetic patients is influenced by the consumption of AGEs, we examined whether AGE consumption also affects IR and whether AGER1 and SIRT1 are involved. RESEARCH DESIGN AND

methodsThe study randomly assigned 36 subjects, 18 type 2 diabetic patients (age 61±4 years) and 18 healthy subjects (age 67±1.4 years), to a standard diet (>20 AGE equivalents [Eq]/day) or an isocaloric AGE-restricted diet (<10 AGE Eq/day) for 4 months. Circulating metabolic and inflammatory markers were assessed. Expression and activities of AGER1 and SIRT1 were examined in patients' peripheral blood mononuclear cells (PMNC) and in AGE-stimulated, AGER1-transduced (AGER1+), or AGER1-silenced human monocyte-like THP-1 cells.

resultsInsulin and homeostasis model assessment, leptin, tumor necrosis factor-α and nuclear factor-κB p65 acetylation, serum AGEs, and 8-isoprostanes decreased in AGE-restricted type 2 diabetic patients, whereas PMNC AGER1 and SIRT1 mRNA, and protein levels normalized and adiponectin markedly increased. AGEs suppressed AGER1, SIRT-1, and NAD+ levels in THP-1 cells. These effects were inhibited in AGER1+ but were enhanced in AGER1-silenced cells.

conclusionsFood-derived pro-oxidant AGEs may contribute to IR in clinical type 2 diabetes and suppress protective mechanisms, AGER1 and SIRT1. AGE restriction may preserve native defenses and insulin sensitivity by maintaining lower basal OS.

Indexed as

Oxidative StressAgedCells, CulturedDiabetes Mellitus, Type 2FemaleGlycation End Products, AdvancedHumansHypoglycemic AgentsInflammationInsulin ResistanceLeukocytes, MononuclearMaleMiddle AgedReceptor for Advanced Glycation End ProductsReceptors, ImmunologicSirtuin 1Glycation End Products, AdvancedHypoglycemic AgentsReceptor for Advanced Glycation End ProductsReceptors, ImmunologicSIRT1 protein, humanSirtuin 1

Identifiers

PMID21709297
PMCPMC3120204
OpenAlexW2061906058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.